| 2026年中报 | 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 特色原料药及中间体(元) | 514,770,531.76 | - | 523,212,213.61 | - | 731,532,152.21 |
| 新药定制研发和生产服务(CDMO)(元) | 1,973,206,923.61 | - | 2,291,374,984.78 | - | 1,970,659,480.91 |
| 贸易类及其他(元) | 87,269,120.75 | 80,936,099.06 | 56,360,134.83 | 56,088,226.03 | 62,088,187.19 |
| 非甾体抗炎药物(元) | - | 239,667,964.01 | - | 276,653,770.94 | - |
| 合同定制(元) | - | 4,176,289,406.93 | - | 3,870,554,542.49 | - |
| 降血糖类药(元) | - | 168,263,485.97 | - | 189,727,475.08 | - |
| 抗感染类药物(元) | - | 332,001,098.59 | - | 304,413,153.40 | - |
| 中枢神经类药物(元) | - | 418,757,554.76 | - | 388,906,029.31 | - |
| 营业成本(元) | |||||
| 特色原料药及中间体(元) | 372,204,806.95 | - | 401,491,691.48 | - | 576,545,264.56 |
| 新药定制研发和生产服务(CDMO)(元) | 1,186,878,624.29 | - | 1,351,447,049.19 | - | 1,161,589,442.50 |
| 贸易类及其他(元) | 66,093,544.54 | 61,115,662.65 | 42,839,774.71 | 46,037,603.70 | 52,772,413.07 |
| 非甾体抗炎药物(元) | - | 150,860,366.36 | - | 171,679,207.86 | - |
| 合同定制(元) | - | 2,460,514,195.63 | - | 2,385,038,893.10 | - |
| 降血糖类药(元) | - | 147,265,162.59 | - | 182,347,389.23 | - |
| 抗感染类药物(元) | - | 314,829,096.07 | - | 321,899,600.24 | - |
| 中枢神经类药物(元) | - | 257,180,614.73 | - | 250,547,699.94 | - |
| 毛利(元) | |||||
| 特色原料药及中间体(元) | 142,565,724.81 | - | 121,720,522.13 | - | 154,986,887.65 |
| 新药定制研发和生产服务(CDMO)(元) | 786,328,299.32 | - | 939,927,935.59 | - | 809,070,038.41 |
| 贸易类及其他(元) | 21,175,576.21 | 19,820,436.41 | 13,520,360.12 | 10,050,622.33 | 9,315,774.12 |
| 非甾体抗炎药物(元) | - | 88,807,597.65 | - | 104,974,563.08 | - |
| 合同定制(元) | - | 1,715,775,211.30 | - | 1,485,515,649.39 | - |
| 降血糖类药(元) | - | 20,998,323.38 | - | 7,380,085.85 | - |
| 抗感染类药物(元) | - | 17,172,002.52 | - | -17,486,446.84 | - |
| 中枢神经类药物(元) | - | 161,576,940.03 | - | 138,358,329.37 | - |
| 毛利率(%) | |||||
| 特色原料药及中间体(%) | 27.70 | - | 23.26 | - | 21.19 |
| 新药定制研发和生产服务(CDMO)(%) | 39.85 | - | 41.02 | - | 41.06 |
| 贸易类及其他(%) | 24.26 | 24.49 | 23.99 | 17.92 | 15.00 |
| 非甾体抗炎药物(%) | - | 37.05 | - | 37.94 | - |
| 合同定制(%) | - | 41.08 | - | 38.38 | - |
| 降血糖类药(%) | - | 12.48 | - | 3.89 | - |
| 抗感染类药物(%) | - | 5.17 | - | -5.74 | - |
| 中枢神经类药物(%) | - | 38.58 | - | 35.58 | - |
| 收入构成(%) | |||||
| 特色原料药及中间体(%) | 19.99 | - | 18.22 | - | 26.46 |
| 新药定制研发和生产服务(CDMO)(%) | 76.62 | - | 79.81 | - | 71.29 |
| 贸易类及其他(%) | 3.39 | 1.49 | 1.96 | 1.10 | 2.25 |
| 非甾体抗炎药物(%) | - | 4.43 | - | 5.44 | - |
| 合同定制(%) | - | 77.11 | - | 76.10 | - |
| 降血糖类药(%) | - | 3.11 | - | 3.73 | - |
| 抗感染类药物(%) | - | 6.13 | - | 5.98 | - |
| 中枢神经类药物(%) | - | 7.73 | - | 7.65 | - |
| 毛利构成(%) | |||||
| 特色原料药及中间体(%) | 15.01 | - | 11.32 | - | 15.92 |
| 新药定制研发和生产服务(CDMO)(%) | 82.77 | - | 87.42 | - | 83.12 |
| 贸易类及其他(%) | 2.23 | 0.98 | 1.26 | 0.58 | 0.96 |
| 非甾体抗炎药物(%) | - | 4.39 | - | 6.07 | - |
| 合同定制(%) | - | 84.77 | - | 85.93 | - |
| 降血糖类药(%) | - | 1.04 | - | 0.43 | - |
| 抗感染类药物(%) | - | 0.85 | - | -1.01 | - |
| 中枢神经类药物(%) | - | 7.98 | - | 8.00 | - |